Quantum-Si Incorporated Class A
As of Oct 22, 2026, Quantum-Si is in Stage 1, the basing phase, now in week 3 (since Oct 5, 2026). It closed at $1.15, 50.9% below its 52-week high and above its 200-day average, which is falling.
Quantum-Si incorporated, a life sciences company, develops proprietary, universal, and single-molecule detection platform applied to proteomics to enable next-gen protein sequencing (NGPS). More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is QSI early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
QSI among Medical Devices88th of 141 by relative strength
All 141 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | TXG | Stage 2 · wk 48 | 99 | −7.8% |
| 2 | RCEL | Stage 2 · wk 13 | 98 | +40.8% |
| 3 | BFLY | Stage 2 · wk 26 | 98 | −26.0% |
| 4 | HAE | Stage 2 · wk 17 | 96 | +8.7% |
| 5 | GKOS | Stage 2 · wk 25 | 96 | +15.1% |
| 6 | AXGN | Stage 3 · wk 2 | 95 | −15.3% |
| 7 | NEOG | Stage 2 · wk 14 | 95 | −11.7% |
| 8 | BVS | Stage 2 · wk 15 | 95 | +10.5% |
| …88 | QSI | Stage 1 · wk 3 | 23 | +51.5% |
Quantum-Si: quick answers
What stage is Quantum-Si in?
As of Oct 22, 2026, Quantum-Si (QSI) is in Stage 1, the basing phase. It entered Stage 1 on Oct 5, 2026 and is in week 3. What the four stages mean
Is Quantum-Si in an uptrend?
Not yet. Quantum-Si is in Stage 1, a base that can come before an uptrend. It trades 20.7% above its 200-day average, which is falling.
How far is Quantum-Si from its 52-week high?
Quantum-Si closed at $1.15 on Oct 22, 2026, 50.9% below its 52-week high of $2.34. Its 52-week low is $0.70.
How has Quantum-Si performed over the past year?
As of Oct 22, 2026, Quantum-Si is down 50.9% over the past year and down 0.9% so far in 2026.
Which sector and industry is Quantum-Si in?
Quantum-Si is in the Medical Devices industry, part of the Health Care sector.
About this companyHealth Care· Medical Devices
Quantum-Si incorporated, a life sciences company, develops proprietary, universal, and single-molecule detection platform applied to proteomics to enable next-gen protein sequencing (NGPS). The company offers Platinum and Platinum Pro NGPS instruments for single-molecule, amino acid level resolution, and automated data analysis; library preparation kits to prepare a customer's protein sample for sequencing; and sequencing kits, which contain the reagents and consumables used to perform NGPS. It also provides Platinum analysis software, a cloud-based solution that automates data analysis workflows and visualizes the sequencing results. The company was founded in 2013 and is headquartered in Branford, Connecticut.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.